Loading...

NervGen Pharma Corp.

NGENF•PNK
HealthcareBiotechnology
$3.90
$-0.07(-1.89%)

NervGen Pharma Corp. (NGENF) Stock Overview

Explore NervGen Pharma Corp.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-0.34
↓ 7.25%
EPS Growth
$-0.34
↑ 5.26%
Operating Margin
0.00%
↓ 40.25%
ROE
-222.53%
↓ 7.25%
Dividend Yield
0.00%
Analyst Recommendations data is not available for NGENFAnalyst Recommendations details for NGENF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

CEO

Mr. Michael P. Kelly

Employees

11

Headquarters

2955 Virtual Way, Vancouver, BC

Founded

2019

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.